linjc16/ctgov huggingface dataset:
The Effect of Non-invasive Hemoglobin Measurement in Hip Surgeries

Study Overview
=================
Brief Summary
-----------------
Bleeding is one of the most important causes of mortality and morbidity in patients. Hb levels are the most prevalently utilized monitoring parameter in hemorrhagic patients in the hemodynamic sense. Hemoglobin determination is studied at laboratories along with blood gasses or complete blood analysis. Recently, non-invasive techniques where measurement is made from the fingertips have been offered for use. One of these techniques is non-invasive hemoglobin (SpHb) measurement. SpHb is used as a trend monitor. Based on the severity of bleeding, the compensatory mechanisms of patients may be disrupted. This situation may lead to lower levels of toleration of anemia during bleeding. The relationship between blood transfusion and mortality is under debate.

Official Title
-----------------
The Effect of Non-invasive Hemoglobin Measurement on Blood Transfusion and Mortality in Hip Surgeries: a Randomized Controlled Trial

Conditions
-----------------
Bleeding, Hemorrhage, Hemodynamic Instability

Intervention / Treatment
-----------------
* Device: non-invasive hemoglobin (SpHb)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-60 years old General anesthesia undergoing hip surgery American society of anesthesiology (ASA) scores I-II-III Exclusion Criteria: Receiving inotropic support Uncontrolled diabetes Arrhythmia Hypothermia Hyperbilirubinemia Jaundice Dark skin pigmentation Without voluntary consent Hypovolemia, hypotension, sepsis, blood diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SpHb<br> | Device: non-invasive hemoglobin (SpHb)<br>* hemoglobin measuring device<br>|
| Control<br> | Device: non-invasive hemoglobin (SpHb)<br>* hemoglobin measuring device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemodynamic Stability | to compare blood transfusion decisions made with SpHb measurement values and with conventional methods in patient who would receive hip surgery. | during the surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | to compare the effects of transfusion results on mortality. | until 3 months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Perioperative Bleeding, Mortality, Hemoglobin, Non-invasive monitoring, Transfusion;, SpHb
Bedside vs. Standard Microbiological Blood Culture Diagnostics - BEMIDIA Study

Study Overview
=================
Brief Summary
-----------------
With a completely bedside blood culture diagnostics system (BACTEC blood culture system in combination with the Accelerate ID/AST System) it is possible to optimize the initial antimicrobial therapy in patients with sepsis and septic shock. Prospective observational, open-label mono-center study to compare a completely bedside blood culture diagnostics system (BACTEC blood culture system in combination with the Accelerate ID/AST System and Curetis Univero System) with standard blood culture diagnostics in patients with sepsis or septic shock.

Official Title
-----------------
Bedside vs. Standard Microbiological Blood Culture Diagnostics - BEMIDIA Study

Conditions
-----------------
Sepsis Septic Shock

Intervention / Treatment
-----------------
* Other: bedside blood culture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a new diagnosed sepsis or septic shock: emergency department, operating theatre, intensive care unit and planed blood culture diagnostics. informed written consent Exclusion Criteria: Pediatric patients (< 18 Years) DNR-order

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: bedside blood culture|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to a significant change of antimicrobial therapy from the time of the diagnosis of sepsis or septic shock |  | Nov. 2016 - Nov. 2017 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sepsis, septic shock, blood cultures, anti-infective therapy
Rapid Medical Donation Programme for Breast Cancer

Study Overview
=================
Brief Summary
-----------------
Treatment of breast cancer has traditionally been based on the primary tumour's features in the breast. Only recently, when cancer returns at other sites, has there been an attempt to biopsy the metastatic disease and change treatments accordingly. A 'repeat biopsy' can be technically difficult, painful and, when possible, only represents a small sample of one of many metastases. Even when one deposit responds to a new treatment, a neighbouring one may continue to grow. There is an urgent need to characterise all deposits, particularly the lethal ones which progress despite all treatments. This study will enable the comprehensive analysis of the metastatic process and the evolution of the breast cancer through the course of its treatment. Patients who have consented during life to donate their tissues for molecular analysis will provide the means for such an analysis. Main aims: To comprehensively and systematically examine metastatic breast cancer by its detailed exploratory molecular characterization to elucidate the possible inter- and intratumoural heterogeneity between the primary tumour and the majority of metastatic sites. To map the natural history of the metastatic breast cancer process

Official Title
-----------------
Rapid Medical Donation Programme for Breast Cancer to Examine Tumour Heterogeneity

Conditions
-----------------
Metastatic Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have completed active treatment (or trials) for metastatic breast cancer. Patients referred to either community or the hospital-based palliative care unit from Royal Marsden National Health Service Foundation Trust. Exclusion Criteria: Lack of capacity / inability to give informed consent. Diagnosis of alternative cancer within the last 5 years other than resected basal cell skin cancer or cervical intraepithelial neoplasia. Patients known to be HIV, Hepatitis B virus or Hepatitis C virus positive on serology . Spongiform encephalopathy (known or suspected CJD) . Eligibility for or current participation in a clinical trial (excluding palliative care trials)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The acquisition of tumour tissue from multiple metastatic sites. |  | Within 6 hours from the time of death. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer
Comparison of Nexfin Pulse Contour Analysis and Cardiac Magnetic Resonance Imaging for the Measurement of Cardiac Output

Study Overview
=================
Brief Summary
-----------------
A growing interest in monitoring cardiac output (CO) non-invasively has emerged, however its determination has been difficult using the standard approaches. The aim of the study is to evaluate the accuracy and precision of pulse contour analysis (PCA) as compared to cardiac magnetic resonance imaging (CMR).

Official Title
-----------------
Is Arterial Pulse Contour Analysis Using Nexfin a New Option in the Non-invasive Measurement of Cardiac Output? - A Pilot Study

Conditions
-----------------
Cardiac Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: indication for CMR Exclusion Criteria: contraindication for CMR claustrophobia no consent obtained

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Medication Adherence in Older People With Psychosis

Study Overview
=================
Brief Summary
-----------------
This study will determine whether Medication Adherence Therapy (MAT) can improve medication adherence and lower the risk of rehospitalization in older patients with psychosis.

Detailed Description
-----------------
Psychoses are among the most common and serious psychiatric disorders. Currently, the most effective treatment for psychoses involves the use of antipsychotic or neuroleptic medications. Unfortunately, pharmacologic regimens often do not achieve their goals because of poor medication adherence. Nonadherence to antipsychotic treatment is a considerable public health problem that leads to myriad clinical and economic burdens, including psychotic relapse, increased clinic and emergency room visits, and rehospitalization. Participants in this study are randomly assigned to receive either MAT or supportive treatment for 12 weeks. MAT is given in 15 sessions and consists of motivational interviewing, education, and social skills and behavior modification. Individual MAT sessions are held in Weeks 1 and 12; small group sessions take place in Weeks 2 through 11. Three monthly booster group sessions begin in Week 16. Participants are assessed at baseline and at 3, 6, and 12 months. Medication adherence, psychopathology, quality of life, medication side effects, health beliefs, and functioning are assessed.

Official Title
-----------------
Medication Adherence in Older Psychotic People

Conditions
-----------------
Psychotic Disorders, Schizophrenia

Intervention / Treatment
-----------------
* Behavioral: Medication Adherence Therapy
* Behavioral: Friendly Support Group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DSM-IV criteria for schizophrenia or schizoaffective disorder Outpatient status at the time of enrollment Currently prescribed maintenance treatment with antipsychotic medication (typical or atypical, oral or depot)

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Medication Adherence Therapy|nan|
|Behavioral: Friendly Support Group|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
To define the safety of cytotoxic T lymphocytes (CTLs) generated from sibling-supplied dendritic cells and lymphocytes and infused into an HIV-infected patient. To determine the efficacy of these CTLs in helping the immune system to fight HIV. With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the body to recognize HIV more readily and increase immune response against the virus.

Detailed Description
-----------------
With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the body to recognize HIV more readily and increase immune response against the virus. Dendritic cells and lymphocytes are obtained from an HIV-negative sibling. HIV-specific CTLs are generated from these cells and then infused into the HIV-infected patient monthly for 6 months. Siblings must be able to donate on multiple occasions, and patients are followed every 2-4 weeks during the study. Patients are screened over 3 months prior to study entry.

Official Title
-----------------
A Pilot Study of HIV Specific Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients With CD4+ T Cells 100-350 Cells/mm3

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Lymphocytes, Activated


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: HLA A2+. Other HLA matching with sibling. CD4 count 100-350 cells/mm3. No active opportunistic infection or malignancy (other than cutaneous Kaposi's sarcoma). Current stable antiviral regimen. Normal lab values and chest x-ray. Donor siblings must have: HLA A2+. HIV negativity. Good venous access. Ability to donate on multiple occasions. Negative status for hepatitis B and C. Exclusion Criteria Concurrent Medication: Excluded: Immunomodulators. Cytokines. Systemic steroids. IV pentamidine. Investigational drugs.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lymphocytes, Activated|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immunotherapy, Adoptive, T-Lymphocyte Subsets, T-Lymphocytes, Cytotoxic, Dendritic Cells
Relationship Between Blood Glucose Variability and Prognosis in Critically Ill Patients

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate the glycemic variation using Continuous Glucose Monitoring System in patients in the intensive care unit, find out the occult hypoglycemia, and investigate the relationship between glycemic variation, especially the incidence of hypoglycemia and prognosis of patients. Meanwhile, the inflammatory factors were measured and the relationship between inflammatory factors and glycemic variation.

Official Title
-----------------
Relationship Between Blood Glucose Variability and Prognosis in Critically Ill Patients

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Diagnostic Test: Continuous Glucose Monitoring System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with history of diabetes; Patients without history of diabetes, but their random blood glucose≧7.8mmol/L or fast blood glucose≧5 mmol/L; The patients hospitalized in care unit (ICU or CCU) for more than 48 hours. Exclusion Criteria: Patient had history of mental illness; Patient was not suitable for using the CGMS; blood glucose > 22.2 mmol/L at admission.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 28 day prognosis | Case-fatality at 28 days | 0-28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute Physiology and Chronic Health Evaluation II score | Acute Physiology and Chronic Health Evaluation II score | 0-28 days | 
| Global registry of acute coronary events risk score | Global registry of acute coronary events risk score | 0-28 days | 
| Twenty-four-hour mean blood glucose | Twenty-four-hour mean blood glucose assessed by CGM | 1-4 days | 
| Mean amplitude of glycemic excursion every 24 h | Mean amplitude of glycemic excursion every 24 h assessed by CGM | 1-4 days | 
| Incidence of hypoglycemia | Incidence of hypoglycemia | 1-4 days |
Treatment of Zollinger-Ellison Syndrome With Prevacid

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.

Detailed Description
-----------------
The aim of this protocol is to study the medical management of acid hypersecretory states including Zollinger-Ellison using Prevacid. The immediate objective is to heal peptic ulcers and eliminate symptoms and in the long term to prevent relapse of symptoms, lesions and complications. Other objectives include observation of the efficacy in controlling gastric acid production and of the safety of high dose, long-term use of Prevacid.

Official Title
-----------------
Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors

Conditions
-----------------
Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia

Intervention / Treatment
-----------------
* Drug: Lansoprazole (Prevacid)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with Zollinger-Ellison syndrome Exclusion Criteria: Pregnant or lactating females

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: single group<br>This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment. | Drug: Lansoprazole (Prevacid)<br>* Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.<br>* Other names: Lansoprazole is marketed as Prevacid.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment. | number of participants with control of gastric acid production | up to 240 months from study enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Median Survival From the Time of Diagnosis. | The median survival from the time of diagnosis | survival or up to 240 months |
GABA and Beta-cell Regeneration

Study Overview
=================
Brief Summary
-----------------
GABA(gamma-Aminobutyric acid) may be used for decreasing anti-gad antibodies and leads beta-cell regeneration.

Detailed Description
-----------------
100 patients with type I diabetes were in 2 groups, had been monitored in a private clinic, number 50 each group, with 30 females and 20 males after the written consent of all patients. All the patients Lied between 18-25 years old with 5-10 years of diabetes onset. The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day. The second group was only on insulin injection in the form of toujeo once daily and Novorapid 3 times daily. In the first group;the investigator measured fasting c peptide levels before and after 6 months of GABA 750mg daily.Also,the investigator measured anti gad antibodies before and after 6 months of treatment. In the second group,the investigator measured c peptide levels and anti-gad antibodies at the beginning of the trial and after 6 months.

Official Title
-----------------
GABA From Medical Nutrition to Pancreatic Beta-cell Regeneration

Conditions
-----------------
Diabetes Mellitus, Type 1

Intervention / Treatment
-----------------
* Drug: GABA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - type 1 diabetes patients age from 18 to 25 years on basal bolus insulin Exclusion Criteria: thyroid problems liver disease kidney disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group1 on GABA<br>The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day. | Drug: GABA<br>* GABA nutritional supplement 750mg per day for 6 months<br>|
| group 2 on just insulin<br>The second group was only on insulin injection in the form of toujeo once daily and Novorapid 3 times daily. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gaba decrease anti gad antibodies | gaba 750 mg daily for type 1 diabetes patients | 6 months | 
| gaba improve c peptide levels | gaba 750 mg pe day for type 1 diabetes patients | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
type 1diabetes, gaba